JP2002502885A5 - - Google Patents

Download PDF

Info

Publication number
JP2002502885A5
JP2002502885A5 JP2000531196A JP2000531196A JP2002502885A5 JP 2002502885 A5 JP2002502885 A5 JP 2002502885A5 JP 2000531196 A JP2000531196 A JP 2000531196A JP 2000531196 A JP2000531196 A JP 2000531196A JP 2002502885 A5 JP2002502885 A5 JP 2002502885A5
Authority
JP
Japan
Prior art keywords
composition
vector
histamine
artery
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000531196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/002702 external-priority patent/WO1999040945A2/en
Publication of JP2002502885A publication Critical patent/JP2002502885A/ja
Publication of JP2002502885A5 publication Critical patent/JP2002502885A5/ja
Pending legal-status Critical Current

Links

JP2000531196A 1998-02-11 1999-02-09 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ Pending JP2002502885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2177398A 1998-02-11 1998-02-11
US09/021,773 1998-02-11
PCT/US1999/002702 WO1999040945A2 (en) 1998-02-11 1999-02-09 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Publications (2)

Publication Number Publication Date
JP2002502885A JP2002502885A (ja) 2002-01-29
JP2002502885A5 true JP2002502885A5 (cg-RX-API-DMAC7.html) 2006-03-30

Family

ID=21806073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000531196A Pending JP2002502885A (ja) 1998-02-11 1999-02-09 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ

Country Status (11)

Country Link
EP (2) EP1053025A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002502885A (cg-RX-API-DMAC7.html)
KR (1) KR20010015915A (cg-RX-API-DMAC7.html)
CN (2) CN100350979C (cg-RX-API-DMAC7.html)
AU (1) AU2663799A (cg-RX-API-DMAC7.html)
CA (1) CA2320302A1 (cg-RX-API-DMAC7.html)
EA (1) EA019099B1 (cg-RX-API-DMAC7.html)
IL (1) IL137765A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ545047A (cg-RX-API-DMAC7.html)
WO (1) WO1999040945A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA991102B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
CA2412847A1 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
EP2236153A3 (en) 2005-01-25 2012-08-22 Five Prime Therapeutics, Inc. Compositons and methods for treating cardiac conditions
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
JP5290290B2 (ja) 2007-07-18 2013-09-18 シルク・ロード・メディカル・インコーポレイテッド 頚動脈血流の逆流を確立する方法およびシステム
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
WO2014160887A2 (en) * 2013-03-28 2014-10-02 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
WO2019089385A1 (en) 2017-11-02 2019-05-09 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US5869230A (en) * 1995-03-30 1999-02-09 Beth Israel Hospital Association Gene transfer into the kidney
WO1999017807A1 (en) * 1997-10-08 1999-04-15 Cobra Therapeutics Ltd. Use of a vasoactive compound in the enhancement of gene delivery
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods

Similar Documents

Publication Publication Date Title
US8178493B2 (en) Method for inducing angiogenesis in a heart of a patient
JP5231587B2 (ja) Vegf−cまたはvegf−d遺伝子またはタンパク質を用いた再狭窄の予防
Mitsos et al. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials
US8455453B2 (en) Use of VEGF-D gene to prevent restenosis
JP2003513942A5 (cg-RX-API-DMAC7.html)
WO2000021548A2 (en) Angiogenically effective unit dose of fgf and method of administering
Stegmann FGF-1: a human growth factor in the induction of neoangiogenesis
US6329348B1 (en) Method of inducing angiogenesis
Gonçalves Angiogenic growth factors: potential new treatment for acute myocardial infarction?
CA2289600A1 (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
US7709450B2 (en) Stimulation of vascularization with VEGF-B-186
Stegmann New approaches to coronary heart disease: induction of neovascularisation by growth factors
EA019099B1 (ru) Способ направленной доставки трансгена в миокард пациента с ишемией миокарда
Webster Therapeutic angiogenesis: a case for targeted, regulated gene delivery
Bashir et al. Angiogenic gene therapy: pre-clinical studies and phase I clinical data
Jejurikar et al. Induction of Angiogenesis by Lidocaine and Basic Fibroblast Growth Factor: A Model forin VivoRetroviral-Mediated Gene Therapy
EP1568375A1 (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
Stegmann et al. Combined Local Angiogenesis and Surgical Revascularization for
Miraliakbari et al. Therapeutic angiogenesis: appropriate for clinical use?
Asahara et al. Molecular and cellular cardiology: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery
Engler Angiogenic Gene Therapy for Coronary Artery Disease
MG-O ACKNOWLEDGEMENTS: FUNDING STATEMENT
AU2002326311A1 (en) Stimulation of vascularization with VEGF-B